Nucleotides Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Nucleotides Market Trends and Insights

Growing Demand from Pharmaceutical and Biopharma Sectors

Oligonucleotide therapeutics shifted from niche to mainstream after the FDA cleared Casgevy, Itvisma, RIVFLOZA, and TRYNGOLZA in 2024, prompting originators to lock in multi-year supply contracts for high-purity nucleotides. Thermo Fisher expanded a Singapore facility in 2025, injecting 500 kg of annual capacity and offering 2-week turnaround times for antisense and siRNA programs. The American Society of Gene and Cell Therapy counted 1,261 RNA-based therapies in active pipelines, a 22% rise year-over-year, underscoring pervasive demand for cytosine, adenine, guanine, and uracil monomers. Messenger-RNA vaccine plants consumed 12,000 t of nucleotides in 2024 and are switching to continuous processing, which heightens near-term raw-material tightness. Convergence of CRISPR, RNAi, and self-amplifying RNA platforms therefore cements structural pull for GMP-grade inputs that food-grade suppliers cannot match.

Rising Adoption in Functional Infant and Medical Nutrition

Regulators continue to endorse nucleotide fortification in formula. The European Food Safety Authority reaffirmed safe use up to 5 mg/100 kcal in 2024^{[1]European Food Safety Authority, “Scientific Opinion on Infant Formula Additives,” efsa.europa.eu} . China’s National Health Commission mandated nucleotides in follow-on formula for 6- to 12-month infants in 2025, instantly lifting demand by 2,400 t per year. Clean-label brands now insist on fermentation-derived grades; lead times stretched to 20 weeks in early 2026, double 2024 norms, as capacity struggled to certify organic standards. Medical-nutrition firms add nucleotide blends at concentrations two-to-three times infant-formula norms, capturing premium pricing. As regulatory mandates intersect with consumer preference for natural inputs, procurement teams reevaluate supplier rosters in favor of dedicated clean-room fermenters.

Inclusion in Livestock and Aquaculture Feed to Replace Antibiotics

The European Union’s 2022 antibiotic ban catalyzed a shift toward immune-modulating nucleotide additives. Poultry trials adding 0.5–1 kg of nucleotide blend per metric ton of feed cut mortality 8–12% and improved feed conversion up to 5%. China approved six nucleotide feed additives for aquaculture in 2025, supporting shrimp and tilapia farms plagued by disease. Aquaculture is particularly responsive because fish have limited endogenous synthesis pathways. Brazilian integrators are running commercial pilots to secure antibiotic-free export premiums. Although the segment is price-sensitive, its volume stability cushions producers against pharmaceutical demand cycles.

Rapid Growth of Oligonucleotide-Based Gene and Cell-Therapy Pipelines

CRISPR-Cas9 approvals spotlight high per-patient nucleotide usage, with each Casgevy dose requiring roughly 250 g of modified oligos. Vertex disclosed USD 80 million of QC infrastructure spending to safeguard supply chain for the launch. Antisense launches need 5–10 kg of API per program, straining mid-tier CDMO capacity. Japan fast-tracked two oligonucleotide drugs in 2025, adding localized demand that domestic suppliers aim to capture. As the pipeline advances, achieving sub-USD 500 per gram cost for phosphorothioate oligos remains the gating hurdle to broad access.

High CAPEX and GMP-Compliance Costs for New Plants

Building a GMP nucleotide plant demands USD 50–200 million in upfront spending plus stringent validation regimes that raise operating overhead 15–20% versus food-grade lines. BioSpring’s Hamburg expansion took 18 months of inspections before revenue flow, illustrating cash-flow drag. Average utilization hovers near 70% because changeovers and batch-release testing idle equipment, below the 85% threshold needed for robust returns. As a result, smaller CDMOs favor partnerships over greenfield builds, concentrating pharmaceutical-grade supply among a dozen qualified players.

Volatile Sugar/Corn-Based Raw-Material Prices

Glucose feedstocks represent up to half of bulk mononucleotide production costs, yet U.S. corn futures swung 18% during 2025 after weather disruptions in Brazil and the Midwest^{[2]U.S. Department of Agriculture, “Grain Market Review 2025,” usda.gov} . Chinese producers faced a 12% cost spike when drought hit Heilongjiang Province, squeezing margins on long-term fixed contracts. European suppliers hedge sugar but paid 6–8% premiums over spot, eroding competitiveness versus Asian rivals. Alternative carbon sources such as methanol remain at pilot scale and await regulatory clearance for food-grade and pharma-grade use. Until diversification matures, producers remain exposed to commodity cycles.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Nitrogenous Base Class: Pyrimidine Dominance Anchored in mRNA Platforms

Pyrimidines accounted for 54.87% of 2025 demand, reflecting the central role of cytidine and uridine in in-vitro transcription for mRNA vaccines and therapeutics. Each conventional mRNA dose uses roughly 1 g of pyrimidines, so vaccine ramp-ups from 2020–2024 locked in multi-year contracts for GMP lots. Self-amplifying RNA formats lower per-dose nucleotide requirements but pipeline growth in gene therapies offsets volume moderation. Purines make up the remaining 45.13% and are especially important in antisense oligos where phosphorothioate-modified adenosine and guanosine enhance stability. Balanced 55:45 pyrimidine-to-purine ratios in infant formula maintain a stable floor for both classes.

In pharmaceutical supply chains, pyrimidines enjoy pricing premiums because GMP lines must mitigate cytidine deamination and uridine oxidation. Thermo Fisher’s 2025 upgrade added dedicated reactors for cytidine triphosphate to address this constraint. Chinese fermentation groups are adding uridine crystallization capacity to capture higher margins, but Western buyers still prefer suppliers with robust impurity profiles validated by EMA norms. As mRNA vaccines diversify into oncology and autoimmune indications, pyrimidine momentum is unlikely to relent.

By Nucleotide Type: Oligonucleotides Lead Growth Amid Therapeutic Momentum

Oligonucleotides are set to expand at 8.22% CAGR through 2031 as 87 late-stage drug candidates advance toward approval. Mononucleotides held 33.40% of the nucleotides market size in 2025, buoyed by infant-formula mandates and growing livestock applications. Dinucleotides remain a flavor-modulating niche tied to savory snacks, while polynucleotides benefit from record NIH RNA-biology funding of USD 3.2 billion for fiscal 2025. 

Custom oligo houses such as BioSpring can deliver modified strands in 2 weeks, outpacing legacy four-to-six-week cycles and commanding 25% price premiums. CDMO shortages continue, evidenced by 12-month reservation queues at several U.S. providers, nudging biotech firms to dual-source supply. Process-scale phosphoramidite synthesis still dominates, but enzymatic alternatives could reduce solvent waste, a shift investors track closely.

By Product Grade: Food Grade Dominates but Pharmaceutical Margins Reshape Strategies

Food-grade material contributed 87.58% of revenue in 2025, anchored by long-standing infant-formula inclusion guidelines and antibiotic-free livestock feed. Diagnostic-grade dNTPs and modified nucleotides serve PCR and sequencing kits, markets sustained by 2.5 billion global PCR tests in 2025. Industrial grade intermediates stagnate as users seek higher consistency. Lab/diagnostic grade lots, though small in volume, capture 40-50% gross margins, motivating Asian bulk suppliers to invest in GMP suites. EMA guidance in 2024 mandating full impurity profiling further narrowed the field to 10–12 compliant vendors. 

By Application: Feed Additives Lead Share While Pharma Drives Margin

Food and animal additives represented 48.62% of 2025 demand, underpinned by EU antibiotic restrictions and China’s formula mandate. The pharmaceutical segment, despite a lower share, will grow fastest on the back of four FDA approvals and a robust late-stage pipeline; each commercial antisense launch needs up to 10 kg of API. Discovery-phase CRISPR libraries and high-throughput screens form a high-margin niche where customers accept USD 50–200 per gram prices. Ajinomoto signaled it would reallocate 60% of capex to pharma-grade capacity over the next three years to capture this margin arbitrage. Volume will remain anchored in feed and food, but profit pools are migrating toward therapeutic uses.

Geography Analysis

Asia-Pacific owned 44.71% of global demand in 2025 and is projected to expand at 7.91% CAGR to 2031. China alone houses the majority of worldwide fermentation capacity, propelled by oligo therapy trials aligned with the country’s precision-medicine roadmap. South Korea’s CJ CheilJedang leverages continuous fermenters to serve both formula and biotech buyers. India focuses on diagnostic reagents yet domestic infant-formula demand is climbing as urban breastfeeding rates fall.

North America is led by the largest oligonucleotide drug pipeline and premium organic-formula segments. Thermo Fisher’s Singapore plant was built to shorten lead times for U.S. clients and safeguard supply chains against trans-Atlantic disruptions. Canada’s formula regulations specify nucleotide levels 20% above Codex minima, resulting in high per-capita consumption. Mexico’s poultry sector is piloting nucleotide feed blends to secure antibiotic-free certifications for exports.

Europe’s demand is characterized by strict clean-label rules that elongate lead times. EMA traceability guidance favors regional suppliers able to document every step, benefitting BioSpring and French CDMOs. Germany, France, and the U.K. host 38 companies developing oligonucleotide drugs, concentrating GMP raw-material usage. The organic-formula boom lifted nucleotide shortages, driving spot premiums. South America and Middle-East and Africa represent lower demand, yet Brazil’s USD 3 billion annual shrimp disease losses spur nucleotide adoption, and Saudi Arabia’s Vision 2030 includes pharma-input localization that could open new capacity bids.

Regulatory Landscape

Nucleotide ingredients used in food, nutrition, and supplements cut across multiple regulatory regimes that depend on end use and product grade. In the European Union, new or non-traditionally consumed nucleotide ingredients can fall under the Novel Food framework set by Regulation (EU) 2015/2283, with authorizations administered through the Union list established via Implementing Regulation (EU) 2017/2470, which sets the entry and labeling bar.

For dietary supplements in the United States, FDA oversight of new ingredients relies on the New Dietary Ingredient (NDI) notification pathway under Section 413 of the FD&C Act, shaping how suppliers structure dossiers when positioning mononucleotides and related materials into supplement channels. Cross-border trade also introduces additional compliance layers, including EPA TSCA import-export requirements for chemical substance imports into the United States, and additional border scrutiny that can apply when shipments are treated as biological materials or research nucleic acids (including through U.S. Customs and Border Protection processes) along with country-specific biosecurity controls. In Australia, importing nucleic acid materials can require meeting Department of Agriculture, Fisheries and Forestry biosecurity import conditions, affecting lead times and documentation for lab and research grade nucleotides shipped into regulated facilities.

Value Chain Analysis

The value chain starts with feedstocks and core inputs, including glucose (from corn or sugar), nitrogen sources, and phosphate reagents, then moves into fermentation or chemical and enzymatic synthesis routes to produce nucleosides and nucleotides (including triphosphates). After that, upstream purification, crystallization, and drying feed into downstream grades and formats, with tighter controls as end markets move toward pharmaceutical and lab/diagnostic use.

Upstream phosphate exposure is a structural risk because phosphorus supply chains are concentrated in a limited set of producing countries, which can amplify cost volatility for producers of nucleotide triphosphates and related intermediates. For pharmaceutical and lab/diagnostic grades, the chain requires tightly controlled GMP operations, validated analytics, and batch release documentation (CoA, impurity profiling) before distribution. Midstream manufacturing splits between bulk fermentation-scale suppliers that serve food and feed grades and specialized CDMOs producing high-purity and modified nucleotides for oligonucleotide therapeutics and molecular diagnostics. Hongene Biotech Corporation is one example of vertical integration, combining raw material synthesis with GMP drug substance and drug product services to reduce handoffs and shorten timelines for pharma customers. Downstream, GMP-grade nucleotides often use cold-chain logistics (often around -20 degrees C), with lead times extending from 6 to 10 weeks for standard GMP dNTPs to 12 to 20 weeks for modified or labeled nucleotides, which supports long-term offtake agreements and dual sourcing among biotechnology hubs.

Market Opportunities and Future Outlook

A major whitespace centers on expanding pharma-grade and enabling-capability supply, including enzymes, building blocks, and integrated production workflows that connect upstream nucleotides to oligonucleotide and RNA therapeutic manufacturing. Recent, concrete capacity and capability moves highlight where investment is concentrating: Asymchem commissioned a fully integrated TIDES commercial supply matrix at its TJ4 site in April 2026 (including over 45,000 L SPPS reactor volume and stated oligonucleotide capacity of at least 180 mol per year), while TriLink (Maravai LifeSciences) opened a GMP enzyme manufacturing facility in Jupiter, Florida, in June 2026 to support integrated IVT supply from R&D to commercial scale. These initiatives align with customer demand for fewer handoffs between nucleotide inputs, enzymes, and downstream synthesis, particularly where quality systems and release timelines drive supplier selection.

Geographic diversification and regional manufacturing footprints also create opportunity for suppliers that can meet GMP and documentation requirements while reducing logistics friction. In Europe, BioSpring began construction activity (July 2025) for a large production facility for pharmaceutical nucleic acid APIs, and in the United Kingdom, 4basebio announced a leased innovation hub and manufacturing facility in Cambridge (March 2026) to expand synthetic DNA output used in research and quality applications. In India, Cohance Lifesciences reported progress (August 2025) on a cGMP oligonucleotide building block facility in Hyderabad with a planned annual capacity of 700 kg, indicating growing local availability of key building blocks and expanding supplier options beyond incumbent East Asian fermentation hubs.